FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 60 filers reported holding FATE THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $24,000 | +41.2% | 1,500 | 0.0% | 0.01% | +66.7% |
| Q2 2018 | $17,000 | +13.3% | 1,500 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $15,000 | -44.4% | 1,500 | -66.7% | 0.00% | 0.0% |
| Q4 2017 | $27,000 | -20.6% | 4,500 | -47.1% | 0.00% | -25.0% |
| Q3 2017 | $34,000 | +61.9% | 8,500 | +30.8% | 0.00% | +100.0% |
| Q2 2017 | $21,000 | -30.0% | 6,500 | 0.0% | 0.00% | -66.7% |
| Q1 2017 | $30,000 | – | 6,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
| Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
| Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
| Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
| DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
| Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
| Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
| Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
| Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |